Skip to main content

Table 1 IgG responses to recombinant Pv32 and GST control proteins in the sera of vivax patients and healthy individuals

From: Immunological characterization of Plasmodium vivax Pv32, a novel predicted GPI-anchored merozoite surface protein

Protein

No. of patient samples (n)

MFIe

95% CIb

No. of healthy samples (n)

MFIe

95% CIb

p valued

Positive

Negative

Total (%)a

Positive

Negative

Total (%)c

Pv32

38

59

96 (39.6)

6252

29.8–49.4

1

95

96 (99.0)

2879

97.0–100

< 0.0001

GST

0

30

30 (0.0)

2895

 

0

30

30 (100)

2880

 

ns

  1. aSero positive rate: % of positive in-patient samples
  2. bConfidence intervals
  3. cSero negative rate: % of negative in healthy samples
  4. dDifferences in the total IgG prevalence for each antigen between vivax patients and healthy individuals were calculated with Student’s t-test, p < 0.05 considered as statistically significant; ns, not significantly different
  5. eMFI: mean fluorescence intensities were divided by cut off value + standard deviation above the mean fluorescence intensity of the malaria naïve samples